Biomea Fusion to Attend H.C. Wainwright Global Investment Conference
May 20, 2022 13:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small...
Biomea Fusion Announces IND Candidate Selection: BMF-500, a Potential Best-in-Class Oral Covalent Inhibitor of FLT3
May 19, 2022 08:00 ET
|
Biomea Fusion, Inc.
BMF-500, an investigational third-generation covalent inhibitor of FLT3, demonstrated picomolar IC50 values across key FLT3 isoforms, potentially making it the most potent inhibitor of its classHighly...
Biomea Fusion Reports First Quarter 2022 Financial Results and Business Highlights
May 16, 2022 07:30 ET
|
Biomea Fusion, Inc.
COVALENT-101 study continues to enroll relapsed/refractory (R/R) acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) patients and has included R/R diffuse large B-cell lymphoma (DLBCL)...
Biomea Fusion to Participate in Bank of America Securities 2022 Healthcare Conference
May 09, 2022 16:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small...
Biomea Fusion Announces Acceptance of Multiple Abstracts at the 2022 ASCO Annual Meeting
April 27, 2022 16:00 ET
|
Biomea Fusion, Inc.
Biomea to present preclinical data in chronic lymphocytic leukemia (CLL) and Trial In Progress (TIP) information for its ongoing COVALENT-101 Phase I trial REDWOOD CITY, Calif., April 27, 2022 ...
Biomea Fusion Reports Preclinical Data on BMF-219 and Trial in Progress Presentations at AACR 2022 Annual Meeting
April 08, 2022 13:00 ET
|
Biomea Fusion, Inc.
Covalent menin inhibitor BMF-219 showed strong cytotoxic activity as a single agent at similar concentrations across multiple preclinical patient derived (PDX) models ex vivo, including diffuse large...
Biomea Fusion Announces Acceptance of Late Breaking Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022
April 06, 2022 17:00 ET
|
Biomea Fusion, Inc.
Biomea to present additional preclinical data from an in vivo study of BMF-219 in type 2 diabetes REDWOOD CITY, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a...
Biomea Fusion to Present at Oppenheimer’s 32nd Annual Virtual Healthcare Conference
March 15, 2022 08:30 ET
|
Biomea Fusion, Inc.
REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel...
Biomea Fusion Announces Presentation of Lead Menin Inhibitor BMF-219 in Diabetes at ADA 82nd Scientific Sessions 2022
March 14, 2022 08:30 ET
|
Biomea Fusion, Inc.
Biomea to present preclinical data from multiple in vivo studiesBiomea plans to initiate a Phase I/II clinical trial of BMF-219 in diabetes in the second half of 2022, subject to submission and...
Biomea Fusion Announces Upcoming Presentations of Preclinical Data in Diffuse Large B-Cell Lymphoma, Multiple Myeloma, and Several KRAS Mutant Solid Tumors for BMF-219 at AACR Annual Meeting 2022
March 08, 2022 18:15 ET
|
Biomea Fusion, Inc.
Irreversible covalent menin inhibitor, BMF-219, exhibited high potency and complete growth inhibition in high-grade B-cell lymphoma and multiple myeloma (MM) preclinical patient derived ex vivo...